- Home
- WU vs BEAM Comparison
WU vs BEAM Comparison
Compare WU & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | BEAM |
|---|---|---|
| Founded | 1851 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WU | BEAM |
|---|---|---|
| Price | $8.16 | $32.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $9.00 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 6.6M | 1.7M |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $4,050,700,000.00 | $24,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $4.73 | $33.77 |
| P/E Ratio | $40.83 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $7.85 | $15.60 |
| 52 Week High | $10.35 | $36.44 |
Technical Indicators
Market Signals| Indicator | WU | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 61.57 |
| Support Level | $7.96 | $25.85 |
| Resistance Level | $8.34 | $34.29 |
| Average True Range (ATR) | 0.25 | 1.81 |
| MACD | -0.04 | 0.17 |
| Stochastic Oscillator | 9.09 | 79.84 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.